May 28
2026 DIA Global Annual Meeting: What the FDA’s Real-Time Data Push Actually Means for Sponsors and CROs
06/15/2026
In this video interview from the 2026 DIA Global Annual Meeting, Kevin Bugin, head of global regulatory policy and intelligence at Amgen and executive sponsor of TransCelerate’s Embedded Pragmatic Trials initiative, reframes the FDA’s continuous review expectations around real-time evidence generation and explains why quality by design—not data cleanup—is what regulators are now demanding.
Watch the full interview from Applied Clinical Trials here.
Related Blog Posts
Why the biggest gains in clinical R&D won’t come from technology
Every few years, the clinical research industry rallies around a new wave of innovation. From decentralised trials and digital biomarkers to AI driven automation, each wave brings genuine capability andpromise. Read the full article featuring Kelsey Jakee on page 38 here.
What happens when protocol data finally flows
Clinical research has no shortage of technology. What it lacks is the ability to scale in ways that allow information to flow automatically across systems and support digitally enabled workflows for critical stakeholders. Read the full article featuring Rob DiCicco from Clinical Trials Arena here.
FDA Conversation on Selective Safety Data Collection
Earlier this month, TransCelerate BioPharma released a summary report focused on selective safety data collection (SSDC) gathered during a joint tabletop exercise convened in late 2025 in collaboration with U.S. Food and Drug Administration’s (FDA) Center for Drug Evaluation and Research (CDER) Center for Clinical Trial Innovation (C3TI). Read the full article from Clinical Research…